Multivariate analysis of TNF-1031 genotype mismatch and CC genotype as a risk factors* for acute GVHD grade 4 in the overall (HLA matched and mismatched) cohort
Variable . | Univariate . | Multivariate . | ||
---|---|---|---|---|
OR (95% CI) . | P . | OR (95% CI) . | P . | |
Recipient age | 0.978 (0.95-1.01) | .109 | 0.975 (0.94-1.01) | .112 |
Donor age | 1.038 (1.00-1.08) | .044 | 1.033 (0.99-1.07) | .105 |
Female to male transplant | 0.610 (0.27-1.38) | .235 | 0.582 (0.24-1.42) | .236 |
Diagnosis ANLL vs ALL | 1.001 (0.57-1.76) | .996 | 1.148 (0.60-2.18) | .673 |
Total body irradiation | 0.909 (0.40-2.07) | .819 | 0.992 (0.39-2.51) | .987 |
Antithymoglobulin | 3.562 (0.99-12.73) | .051 | 2.246 (0.45-11.15) | .322 |
Cyclosporine vs tacrolimus | 1.336 (0.75-2.37) | .321 | 1.516 (0.80-2.86) | .198 |
Relapse | 0.115 (0.03-0.48) | .003 | 0.154 (0.04-0.65) | .011 |
HLA match | 0.465 (0.24-0.92) | .027 | 0.765 (0.35-1.67) | .502 |
Genotype CC | 4.336 (1.7-11.1) | .002 | 3.888 (1.39-10.90) | .010 |
Genotype mismatch | 2.905 (1.65-5.1) | .00023 | 2.307 (1.18-4.52) | .015 |
Variable . | Univariate . | Multivariate . | ||
---|---|---|---|---|
OR (95% CI) . | P . | OR (95% CI) . | P . | |
Recipient age | 0.978 (0.95-1.01) | .109 | 0.975 (0.94-1.01) | .112 |
Donor age | 1.038 (1.00-1.08) | .044 | 1.033 (0.99-1.07) | .105 |
Female to male transplant | 0.610 (0.27-1.38) | .235 | 0.582 (0.24-1.42) | .236 |
Diagnosis ANLL vs ALL | 1.001 (0.57-1.76) | .996 | 1.148 (0.60-2.18) | .673 |
Total body irradiation | 0.909 (0.40-2.07) | .819 | 0.992 (0.39-2.51) | .987 |
Antithymoglobulin | 3.562 (0.99-12.73) | .051 | 2.246 (0.45-11.15) | .322 |
Cyclosporine vs tacrolimus | 1.336 (0.75-2.37) | .321 | 1.516 (0.80-2.86) | .198 |
Relapse | 0.115 (0.03-0.48) | .003 | 0.154 (0.04-0.65) | .011 |
HLA match | 0.465 (0.24-0.92) | .027 | 0.765 (0.35-1.67) | .502 |
Genotype CC | 4.336 (1.7-11.1) | .002 | 3.888 (1.39-10.90) | .010 |
Genotype mismatch | 2.905 (1.65-5.1) | .00023 | 2.307 (1.18-4.52) | .015 |
Both are independent risk factors, with competing effects from HLA matching and relapse.